Abbott's freestyle libre® continuous glucose monitoring systems obtain significantly expanded coverage for medicare beneficiaries

More medicare beneficiaries than ever before who are living with diabetes and use insulin1 will now be eligible for reimbursement when using abbott's (nyse: abt) freestyle libre® portfolio3,4 – the most prescribed and affordable continuous glucose monitoring system (cgm) in the united states
ABT Ratings Summary
ABT Quant Ranking